Sino Biopharmaceutical
Philip Duong currently serves as the Head of International Business at Sino Biopharmaceutical Limited, a position held since 2024, and has been a Board Member at Karolinska Development and Treadwell Therapeutics, Inc. since 2022 and 2021, respectively. Previously, Philip held various leadership roles at Sino Biopharmaceutical Limited, including Head of Overseas Business Development and Alliance and Head of Investments, from 2020 to 2023, and served as the Head of Strategy and China Operations at invoX Pharma Limited from 2022 to 2023. Philip gained extensive experience in investment banking through positions at Deutsche Bank and Merrill Lynch from 2012 to 2020. Education was completed at the University of Toronto.
This person is not in any teams
This person is not in any offices
Sino Biopharmaceutical
1 followers
Sino Biopharmaceutical Limited is an investment holding company principally engaged in the medicine products business. The Company operates through three business segments. The Modernized Chinese Medicines and Chemical Medicines segment is engaged in the manufacture, sales and distribution of modernized Chinese medicine products and western medicine products. The Investment segment is engaged in long term investments. The Others segment is engaged in the provision of research and development activities and services to third parties, as well as related healthcare and hospital business. The Company is also involved in the property holding, the sales of health food, the manufacture and optometry of optical glasses, as well as the retail and wholesale of optical and auditory products through its subsidiaries.